Olema Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Olema Pharmaceuticals (OLMA).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$43Upside to Avg. PT+298.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$52→$46
Aug 11, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$62→$59
Aug 11, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$38→$36
May 13, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$38→$35
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
Mar 19, 2026	Jefferies	Dennis Ding	Assumes	Buy	$43→$40
Mar 18, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$55→$58
Mar 18, 2026	Goldman Sachs	Richard Law	PT Cut	Buy	$38→$27
Mar 17, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$60→$62
Mar 17, 2026	Guggenheim	Brad Canino	PT Cut	Buy	$40→$38
Mar 9, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$45→$38
Feb 11, 2026	Stifel	Laura Prendergast	Initiate	Buy	$48
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$45
Jan 7, 2026	Piper Sandler	—	Initiate	Overweight	—
Dec 12, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$21→$60
Dec 11, 2025	Oppenheimer	Matthew Biegler	PT Raise	Outperform	$45→$48
Dec 11, 2025	Goldman Sachs	Richard Law	PT Raise	Buy	$26→$38
Dec 11, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$36→$45
Nov 21, 2025	Goldman Sachs	Richard Law	PT Raise	Buy	$18→$26
Nov 18, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$28→$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target from $52 to $46.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.

Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Peer Perform rating.

Benzinga Newsdesk

PRO
Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

Jefferies analyst Dennis Ding assumes Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and lowers Price Target of $40.

Benzinga Newsdesk

Olema Pharmaceuticals inc

Olema Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

PRO
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

PRO
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

PRO
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

PRO
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

PRO
Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

People Also Watch

People Also Watch

Benzinga

Benzinga

Olema Pharmaceuticals inc

Olema Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

PROCitigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

PROHC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

PROGuggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

PROWolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

PROJefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

PRO
Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

PRO
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

PRO
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

PRO
Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

PRO
Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40